Ticker Details
Kura Oncology, Inc. Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers.
IPO Date:	September 16, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$781.72M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.38 | 2.81%
Avg Daily Range (30 D):	$0.21 | 2.52%
Avg Daily Range (90 D):	$0.24 | 2.56%

Institutional Daily Volume
Avg Daily Volume:	.56M
Avg Daily Volume (30 D):	1.24M
Avg Daily Volume (90 D):	1.23M

Trade Size
Avg Trade Size (Sh.):	92
Avg Trade Size (Sh.) (30 D):	85
Avg Trade Size (Sh.) (90 D):	82

Institutional Trades
Total Institutional Trades:	3,069
Avg Institutional Trade:	$1.84M
Avg Institutional Trade (30 D):	$1.63M
Avg Institutional Trade (90 D):	$1.93M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.97M
Avg Closing Trade (30 D):	$1.89M
Avg Closing Trade (90 D):	$1.97M
Avg Closing Volume:	136.67K

News

Apr 3, 2026 @ 11:30 AM Kura Oncology Reports Inducement Grants Under Nasd... Source: Na

Dec 4, 2025 @ 5:20 PM Blood Cancer Therapeutics Reach Critical Commercia... Source: Prnewswire

Nov 25, 2025 @ 10:16 PM KOMZIFTIâ„¢ (ziftomenib) Added to National Com... Source: Kura Oncology And Kyowa Kirin

Oct 18, 2025 @ 7:23 AM Kura Oncology Announces Preliminary Data from Its ... Source: Kura Oncology

Oct 10, 2025 @ 8:54 AM Menin Inhibitors Drug Market Report 2025: Price, S... Source: Researchandmarkets.Com

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-3.18	$-.92	$-3.18
Diluted EPS	$-3.18	$-.92	$-3.18
Revenue	$67.48M	$17.34M	$67.48M
Gross Profit
Net Income / Loss	$-278.67M	$-81M	$-278.67M
Operating Income / Loss	$-303.63M	$-86.27M	$-303.63M
Cost of Revenue
Net Cash Flow	$-75.36M	$53.81M	$-75.36M
PE Ratio